Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Main Authors: Gavriatopoulou, Maria, Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Eleutherakis-Papaiakovou, Evangelos, Papatheodorou, Athanasios, Kanellias, Nikolaos, Migkou, Magdalini, Fotiou, Despina, Dialoupi, Ioanna, Roussou, Maria, Kokkali, Nikoletta-Aikaterini, Kastritis, Efstathios, Dimopoulos, Meletios A.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Correspondence
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7052253/
https://ncbi.nlm.nih.gov/pubmed/32123158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0297-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares